Q1 FY27 earnings call · August 15, 2026

Natco Pharma Ltd (NATCOPHARM) Q1 FY27 Earnings Call: Plans Rs.2,000 Crore Fundraise, Maintains Rs.750 Cr PAT Guidance

Cofacto ResearchPublished August 15, 20265 min read
Quick summary

Natco Pharma Ltd held its Q1 FY27 earnings call on August 14, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Revenue Normalises After Lenalidomide Peak; Base Business Holds Firm

  • Consolidated revenue of Rs.794.4 Cr — down 43% YoY from Rs.1,390.6 Cr, driven by negligible Revlimid contribution; double-digit base business growth partially offset the decline.
  • EBITDA of Rs.235.7 Cr (30.9% margin) — improved QoQ from Q4 FY 2025-2026 on stronger international/domestic performance and lower operating costs.
  • Consolidated PAT of Rs.206.5 Cr — normalized PAT grew 34% QoQ after stripping a Rs.115 Cr one-time deferred tax benefit recorded in Q4 FY 2025-2026.
  • Other expenses declined sharply — due to lower R&D and legal costs in Q1; management warned this run rate is not sustainable and advised an annual view.
  • Domestic formulation revenue of Rs.136 Cr — Brazil business reached Rs.178 Cr (+180% YoY), Canada contributed Rs.56 Cr.
  • Net cash of Rs.1,400 Cr — down from Rs.3,500 Cr at FY 2025-2026 close after ~Rs.3,000 Cr in subsidiary stake acquisitions over the past year.

Rs.2,000 Crore Fundraise Planned to Fuel M&A Land Monetisation on Hold

  • Rs.2,000 Cr fundraise under evaluation — management is exploring QIP, rights issue, and other options; board has authorised consideration of all routes to finance potential acquisitions.
  • Two acquisition opportunities under review — "a smaller piece in India and a very large opportunity outside India"; no specific geographies or timelines disclosed.
  • Organic capex run rate of Rs.250-300 Cr per annum — funded from internal accruals; no specific FY assigned by management.
  • Land bank held, but 15-20% tied up in litigation — management prefers to resolve all disputes before selling to maximise price; no monetisation timeline provided.
  • Net cash of Rs.1,400 Cr — provides flexibility; management noted the decline from Rs.3,500 Cr at March FY 2025-2026 reflects aggressive investment in strategic stakes.

Adcock Stake Raised to 49%; Brazil Oncology Pipeline Gains Traction

  • Adcock Ingram stake increased to 49% — Natco acquired an additional 13.25% in July 2026, up from 25.75% as of 30 June 2026, strengthening its South Africa position.
  • Adcock profit share jumped to Rs.80 Cr in Q1 — vs. normal run-rate of Rs.35-40 Cr/quarter, driven by a strong flu season in Brazil; management cautioned against extrapolating this level.
  • Brazil revenue grew 180% to Rs.178 Cr — oncology pipeline is the primary growth driver; additional meaningful launches planned in calendar 2027, subject to patent litigation outcomes.
  • South Africa base business contributed 35-40% of Q1 earnings — pipeline synergies through Natco's portfolio and Indian partner alliances expected over the next 2-3 years from call date.
  • Two dossiers filed for the 49%-owned entity — launch targeted around FY 2027-2028, consistent with a typical registration timeline of 18-24 months.
  • No near-term opportunity to increase stake beyond 49% — the other investor holds 51% and is not looking to sell; Natco retains a first right of refusal.
  • Demerger of Natco Crop Health Sciences delayed — expected completion now ~March 2027 (Q4 FY 2026-2027), pushed from December 2026 due to a potential fundraising activity.

E‑Genesis Xenotransplant Milestone; Long-Cycle R&D Strategy Targeted at 30-40x Returns

  • E‑Genesis treated 500 patients; two survived >8 months on pig kidney — management expects "very exciting updates" within FY 2026-2027 on this most valuable innovation asset.
  • Internal ANDA filing target of 8-10 per year — including 2-3 first-to-file (FTF) opportunities; at least 1-2 FTFs expected in FY 2026-2027 over and above the existing pipeline.
  • 70-80% of R&D allocated to long-cycle projects — payoff horizon between FY 2028-2029 and FY 2035; these 8-10 year programmes target ~30-40x returns vs. 15-20% for short-term projects.
  • Carfilzomib launch on track for calendar 2027 — upgrade expected by end of calendar 2026; remains a key pipeline catalyst.
  • Ola Parib litigation: trial date scheduled in next few months — exclusivity determination not yet decided, as the 30-month period was exceeded.

Crop Health Targets FY27 Break-Even; Semaglutide Generates ~Rs.2 Cr/Month

  • Revlimid contribution negligible in Q1 FY 2026-2027 — the product that previously drove significant revenue has largely run off.
  • Crop Health Sciences reported an EBITDA loss in Q1 — management targets break-even for FY 2026-2027; Q2 expected to be significantly better due to delayed rains (El Niño impact).
  • Crop Health revenue guidance maintained for FY 2026-2027 — targeting gross sales between 33 and 34 (unit unspecified); FY 2025-2026 crop health revenue was Rs.138 Cr, with Q1 FY 2026-2027 at ~Rs.40 Cr.
  • Semaglutide brand generated ~Rs.2 Cr/month in Q1 — the market remains intensely competitive; product is not losing money but not earning significant profit; pricing stability expected in the next few months.
  • Two exclusive US launches planned for FY 2027-2028 — product names under NDA; CTPAR technical exports have commenced but are not yet significant.
  • Export revenue declined ~14% QoQ in constant currency — due to seasonality and lower Comirnaty demand; no specific geography or product-level guidance provided.

PAT Guidance of ~Rs.750 Cr Maintained; Q1 Strength Called a One-Time Flu Bump

  • FY 2026-2027 PAT guidance unchanged at ~Rs.750 Cr — management maintained the target despite strong Q1, cautioning against extrapolating the quarterly run rate.
  • Q1 strength attributed to a one-time flu season bump — normal quarterly profit from the entity is ~Rs.100 Cr; base business contributed ~$150 M in constant currency.
  • Domestic base business expected to grow ~25% in remaining FY 2026-2027 quarters — vs. normal run-rate of Rs.107 Cr/quarter.
  • Higher R&D and legal costs expected in coming quarters — Q1 expense level was unusually low and is not a sustainable run rate.
  • 49% technology increase flagged as part of base expectations — likely relating to equity stake or technology fee step-up moving forward.
  • Semaglutide dossier not yet filed in Canada or Brazil — both markets remain pending; no timeline provided for filings.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.